function and sickness behavior were assessed after the challenge, and peripheral and central inflammatory responses were measured. Results: Euflammation reduced LPS-induced peripheral and central inflammation in all mice; however, neuroinflammation was less attenuated in tumor-bearing mice compared with tumor-free controls. LPS-induced lethargy and cognitive impairments were more pronounced among tumor-bearing mice and were effectively attenuated with euflammation. Cognitive changes were independent of brain-derived growth factor gene expression in the hippocampus. Conclusion: These results suggest that induction of euflammation may be useful in alleviating the negative side effects of bacterial-based tumor treatments and in potentially attenuating common behavioral comorbidities associated with cancer or other chronic diseases.
threshold infectious stimuli in the periphery (e.g., Escherichia coli ) attenuate circulating cytokines, neuroinflammatory, and sickness behavior responses to subsequent immune challenges [2, 3] . Notably, this novel "euflammatory" protocol diverges from endotoxin or lipopolysaccharide (LPS) tolerance/conditioning in that euflammation does not induce sickness behavior during the conditioning phase. Currently, repeated low-dose injections of other types of bacteria (e.g., Salmonella , Clostridium [4] ) are used to effectively reduce tumor mass and prolong survival in cancer patients by either activating anticancer immunity or as tumor-targeting vehicles [5, 6] . Indeed, treatment of oral cancer in this manner has mounting potential [7] . However, this treatment occasionally causes significant illness behavior in cancer patients, thereby causing premature termination of the treatment [8] . Therefore, the application of a euflammation protocol may ameliorate treatment discontinuation due to negative side effects.
Cancer patients and survivors exhibit mild to moderate cognitive impairments compared with cancer-naïve controls [9] . These cognitive impairments can persist as long as 20 years after cancer treatment [10] and significantly reduce quality of life [11] and employability [12] . While cancer treatments and stress contribute to mental health issues associated with cancer, pretreatment clinical findings and tumor models indicate that tumor biology also plays a significant role [13, 14] . Cognitive issues are documented in the oral cancer population specifically [15, 16] , even prior to cancer treatments (chemotherapy, radiation) [17] , corroborating this causal role of tumor biology. Cognitive decline in cancer patients is detrimental to overall long-term quality of life. Furthermore, behavioral responses to homeostatic challenges (e.g., stressors) unmask further behavioral difficulties [14] . For example, following a cold temperature stressor challenge, breast cancer patients and survivors had greater difficulty recalling narrative information and lacked the stress-induced benefits to emotional memory recall compared with cancer-free controls [18] . Likewise, abdominal surgery (i.e., an immune stressor) elicits a greater circulating proinflammatory cytokine response among colon cancer patients compared to cancer-free controls [19] . Thus, a prior cancer experience alters immune responses to challenges. Therefore, in addition to the potential improvements in side effects caused by antitumor bacterial treatments, euflammation may also ameliorate exaggerated brain and immune consequences to inevitable immune challenges experienced by cancer patients (e.g., viral infection, surgery).
Rodent models of cancer demonstrate that tumors are sufficient to induce cognitive impairments and neuroinflammation [20, 21] . In one rodent model of breast cancer, neuroinflammatory responses to an acute, peripheral bacterial mimetic (LPS) were elevated among tumorbearing rats relative to tumor-free controls [22] . Taken together, these clinical and basic studies suggest that inflammatory responses to immune challenges may be altered by cancer and contribute to cancer-associated behavioral comorbidities.
This study was designed to test the effectiveness of an established euflammation protocol [2, 3] in reducing central and peripheral inflammation and cognitive consequences of an immune challenge after tumor development. Specifically, this work focuses on modulation of the euflammatory network by a peripheral tumor. In addition, the extent to which euflammation modulates post-LPS behavior was extended from sickness behaviors to cognition and the positively associated brain-derived neurotrophic factor [23] . Finally, the inverse relationship, i.e., that euflammation may influence tumor growth, was also tested.
Materials and Methods

Animals
Male 7-to 8-week-old endotoxin-sensitive [24] C3H/HeNCrl mice (Charles River, Wilmington, MA, USA) were housed 3/cage and acclimated to the temperature-controlled (22 ± 1 ° C) vivarium for 1 week under a 12-h light:12-h dark cycle (lights on at 06.00 h EST). Rodent chow (Harlan 7912) and water were available ad libitum throughout the study, and cotton nestlets were provided for nest building. All mice were acclimated to handling twice weekly prior to experimental procedures. All experiments were approved by the Ohio State University Institutional Animal Care and Use Committees and carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals [25] . All efforts were made to minimize animal suffering and to reduce the number of mice used. Forty-eight mice were used for Experiment 1 and 30 were used for Experiment 2.
Cells
The murine oral cancer cell line AT-84, originating from a spontaneous oral tumor in C3H mice, was generously provided by Dr. Shulin Li at MD Anderson (Houston, TX, USA). Cells were grown in RPMI-1640 with 10% FBS, 2 m M L -glutamine, 0.1 m M nonessential amino acids, 10 m M N-2-HEPES buffer, 100 units penicillin/mL, and 100 μg streptomycin/mL at 37 ° C with 5% CO 2 [26] .
Experimental Design
Effects of Tumors on Euflammation: Experiment 1 Between 8 and 9 weeks of age, half of the mice were inoculated with tumor cells ( n = 24; "Tumor") or PBS vehicle ( n = 24; "No , subsets of the mice received the 3-day euflammation protocol ("Euflamm") or the control protocol ("No euflamm") followed the next day by an acute inflammatory challenge (LPS) or control (PBS). Next, cognitive function was assessed in all mice (1.5-5.5 h after challenge) followed immediately by tissue collection (5.5 h after challenge). Mice were pseudorandomly ordered by treatment to eliminate potential temporal biases. Blood, hippocampus, hypothalamus, frontal cortex, spleen, and tumors were collected for this experiment. One mouse from the tumor group died spontaneously and was removed from the study; another mouse in the tumor group was removed because the tumor was <125 mm 3 (see Fig. 1 a for the experimental timeline and sample sizes).
Effects of Euflammation on Tumor Growth: Experiment 2 Between 8 and 9 weeks of age, two thirds of the mice received the 3-day euflammation protocol ( n = 20), and the other third received the control treatment ( n = 10). The next day, all mice were inoculated with either tumor cells or PBS vehicle. An acute inflammatory challenge or control injection occurred 23 days later, when tumors were approximately 800 mm 3 . The hippocampus, hypothalamus, and tumors were collected for this experiment (see Fig. 1 b for the experimental timeline and sample sizes). 
Tumor Induction
Mice were first anesthetized (isoflurane inhalant) and then injected in the flank (s.c.) with either 50 μL of a suspension of 1.5 × 10 6 AT-84 cells or PBS vehicle [26] . Ear notches were made at this time for identification purposes. This procedure results in nonmetastatic oral squamous cell carcinomas [27] , the most common type of oral cancer in humans. This is a validated syngeneic model, permitting the use of mice with intact immune systems [28] . Body mass and tumor volume were measured twice/week. The longest diameter of the tumor (A) and the perpendicular diameter (B) were used to estimate tumor volume by the formula:
Euflammation
The euflammation protocol has been previously described [2] . Briefly, the protocol consisted of 3 increasing, consecutive daily injections of E. coli (strain LT004; i.p.): 2 × 10 7 CFUs on day 1, 25 × 10 7 CFUs on day 2, and 100 × 10 7 CFUs on day 3. E. coli was suspended in 100 μL sterile PBS for injection. Mice without euflammation received 100 μL i.p. injections of PBS at the same time.
Acute Inflammation Induction
One day after the euflammation protocol (9.00 h EST), mice were injected intraperitoneally with bacterial LPS ( E. coli 0111:B4, 250 μg/kg) or 100 μL of sterile PBS.
Tests of Cognitive Abilities
Spontaneous Alternation This spatial working memory test was performed based on a modified version of a previously described procedure [29] . A Ymaze, consisting of 3 equal-length gray acrylic arms (40 L × 8 W × 15 H cm) at angles of 120° from each other, was used. Mice were placed initially in the center (10.30 h EST) and allowed to explore the entire maze for 3 min. This test is based on the natural tendency of rodents to methodically explore relatively novel arms rather than the most recently explored arms. The series of arm entries was recorded using an overhead camera and tracked using ANY-Maze video tracking software (Stoelting Co., San Diego, CA, USA). A successful alternation was defined as successive entries into each of the 3 arms in any order. Percent spontaneous alternation was calculated as the ratio of successful alternations over total possible alternations (defined as the total number of arm entries minus 2) and multiplied by 100.
Novel Object Recognition This nonspatial cognitive task is mediated by the temporal cortex and is based on the rodents' preference to investigate novel versus familiar objects. This task was performed as previously described [15] . Briefly, after completing the spontaneous alternation test, mice were allowed to investigate 2 identical objects (upright 50 mL conical tubes filled with sand) for 10 min in a clean cage, after which they were returned to their home cage. Three hours later, mice were returned to the clean cage, but one familiar object was replaced with a novel object (hockey puck). Relevant to mouse strains prone to retinal degeneration such as C3H, visual input is not required for novel object recognition when objects differ by various sensory modalities (size, shape, color, material, texture) [30] and has been used successfully in this strain [30] [31] [32] . Investigative behavior was scored for 5 min. All objects were rinsed with 70% ethanol between trials. Videos were scored using Etholog v. 2.2 freeware (Sao Paulo, Brazil). Investigation was defined as object-directed behavior with the nose <1 cm from an object and vibrissae moving. A novel object discrimination index was calculated: (time spent investigating novel object -time spent investigating familiar object)/(total time spent investigating either object) × 100.
Tissue Collection
Following rapid decapitation, trunk blood was collected in heparin-lined blood collecting tubes (14.30 h EST). Blood was used to measure circulating cytokine concentrations. The brains were removed, and the hypothalamus was dissected and flash frozen, the rest of the brain was sagitally bisected and stored in RNALater stabilization solution for later dissection of the hippocampus and frontal cortex. All samples were frozen at -80 ° C until neuroinflammatory gene expression assessment. Tumors and spleens were removed and weighed.
Plasma Cytokine Concentrations
To compare circulating inflammatory responses among treatments, interleukin (IL)-1β, IL-6, keratinocyte chemoattractant (CXCL1), and tumor necrosis factor (TNF-α) were measured in plasma samples in duplicate using a multiplex fluorescent bead array (Mouse Inflammatory V-Plex Panel; Mesoscale Discovery, Rockville, MD, USA) according to the manufacturer's protocol. Detection thresholds were 0.11, 0.61, 0.24, and 0.13 pg/mL, respectively. All samples were detectable for all cytokines. Intra-assay and interassay variations were each <10%.
Quantitative RT-PCR
Total RNA was extracted from the individual brain regions collected using Qiagen RNeasy mini kits (CA, USA). RNA concentrations were measured and 260/280 ratios were determined to be 1.8-2.0 (NanoDrop, DE, USA). Total RNA was reverse transcribed using SuperScript First-Strand kits (Invitrogen, NY, USA) according to the manufacturer's protocol. Four genes of interest were chosen based on their established role in neuroinflammation-induced cognitive behavioral effects ( Il1β, Il6, Tnfα, Cd11b ) [33] . Bdnf (brain-derived neurotrophic factor) gene expression was examined in the hippocampus based on its role in promoting cognition through neuronal health and proliferation [34] . Mouse TaqMan gene expression assays were purchased from Applied Biosystems (Carlsbad, CA, USA) with probes labeled with 6-FAM and MGB (nonfluorescent quencher) at the 5 ′ and 3 ′ ends, respectively: 78 Cary, NC, USA) when variance was normal. Nonparametric Mann-Whitney U tests were used when variance was not normally distributed. Repeated measures ANOVAs were used to compare changes in body mass over time. Data were determined to be statistically significant when p ≤ 0.05 and are presented as means ± standard error of the mean.
Results
Experiment 1: Effects of Tumors on Euflammation
Tissue Masses All mice gained weight over the 3 weeks of tumor growth prior to the euflammation treatment ( Fig. 2 a; F 3, 135 = 110.8, p < 0.0001); tumor growth did not affect body mass ( p > 0.05). The 3-day euflammation protocol ("Euflamm day 1" through "Pre-LPS") interacted with time to affect body mass ( Fig. 2 b; F 1, 43 = 5.2, p < 0.05) such that mice without euflammation gained weight over this time period, whereas those that received euflammation did not. Body weight changed over the 4-h post-LPS treatment period ( Fig. 2 b; F 1, 38 = 56.8, p < 0.0001), driven primarily by a tendency for weight loss in all LPS-treated mice ( F 1, 38 = 3.5, p = 0.07).
Neither euflammation nor LPS treatments influenced final tumor mass ( Fig. 2 c; p > 0.05). Both euflammation ( F 1, 39 = 16.0; p < 0.001) and LPS treatment ( F 1, 39 = 7.9; p < 0.01) independently increased spleen mass, whereas tumors did not ( Fig. 2 d; p > 0.05). The LPS-induced increase in spleen weight appeared to be driven by all pairwise comparisons, except for the tumor-free euflammation group ( p > 0.05). Circulating Cytokines Both euflammation and LPS treatments independently altered circulating IL-1β ( Fig. 3 a; F 1, 31 = 17.6; p < 0.001, F 1, 31 = 36.3; p < 0.0001), IL-6 ( Fig. 3 b; F 1, 33 = 11.6, p < 0.01; F 1, 33 = 13.1, p < 0.01), CXCL1 ( Fig. 3 c; . However, tumors tended to attenuate these euflammation-induced reductions in IL-1β after LPS relative to tumor-free controls ( Fig. 3 a; U = 7 ; p = 0.08). This attenuation was not observed in the other circulating cytokines ( p > 0.05 in all cases). Tumors also tended to increase LPS-induced TNF-α among mice without euflammation ( Fig. 3 d; t 10 = 2.0; p = 0.08). All PBS-treated mice had comparable IL-1β, IL-6, and TNF-α regardless of euflammation and tumor treatments ( p > 0.05). Euflammation decreased CXCL1 among all PBS-treated mice ( Fig. 3 c; F 1, 13 = 5.3, p < 0.05), which was driven primarily by the trend within tumor-bearing mice ( t 6 = 1.7, p = 0.1). Neuroinflammation Interleukin-1β. Both euflammation and LPS treatment independently altered hippocampal Il1β ( Fig. 4 a; F 1, 35 = 8.7, p < 0.01, F 1, 35 = 33.3, p < 0.0001) as well as their interaction ( F 1, 35 = 12.3, p < 0.005) such that euflammation attenuated LPS-induced increases in Il1β mRNA expression in both tumor-free ( t 8 = 2.7, p < 0.05) and tumorbearing mice (U = 2, p < 0.05). In the overall ANOVA, LPS treatment significantly increased hypothalamic ( Fig. 4 b; F 1, 38 = 34 .5, p < 0.0001) and frontal cortex ( Fig. 4 c; F 1 , 37 = 27.3, p < 0.0001) Il1β. However, relative to PBS controls, LPS failed to significantly increase Il1β after euflammation in the hippocampus and in the frontal cortex of LPS-treated tumor-bearing mice. Euflammation only attenuated LPS-induced Il1β increases in tumor-free mice relative to no euflammation controls in the frontal cortex ( Fig. 4 c ; U = 4, p < 0.05). In this brain region, the interactions between euflammation and LPS treatment ( F 1, 37 = 4.3, p < 0.05) and between euflammation and tumor treatment ( F 1, 37 = 5.4, p < 0.05) were statistically significant. Within the PBS-treated mice, euflammation increased hypothalamic Il1β mRNA ( Fig. 4 b; F 1, 19 = 6.1, p < 0.05), although pairwise comparisons within the tumor treatments were not significantly different ( p > 0.05 in both cases). PBS-treated mice were not affected by euflammation treatment in the hippocampus or frontal cortex for this gene.
Interleukin 6. Both euflammation and LPS treatment independently altered hippocampal, hypothalamic, and frontal cortex Il6 mRNA ( Fig. 4 d- Tumor Necrosis Factor α. Both euflammation and LPS treatment independently altered hippocampal and frontal cortex Tnfα mRNA ( Fig. 4 g, i) (hippocampal: F 1, 36 = 6.4, p < 0.05; F 1, 36 = 18.4, p < 0.0005; frontal cortex: F 1, 37 = 19.1, p < 0.0001; F 1, 37 = 72.6, p < 0.0001) as well as their interaction (hippocampal: F 1, 36 = 8.9, p < 0.01; frontal cortex: F 1, 37 = 22.6, p < 0.0001). Thus, euflammation attenuated LPS-induced increases in Tnfα relative to no euflammation for both tumor-free (hippocampal: t 8 = 3.1, p < 0.05, frontal cortex: t 9 = 3.4, p < 0.01) and tumor-bearing (hippocampal: U = 0, p < 0.01; frontal cortex: t 9 = 3.4, p < 0.01) mice in these two brain regions. LPS failed to significantly increase Tnfα in the tumorfree mice ( p > 0.05 in both regions), but not the tumorbearing mice (hippocampal: t 10 = 3.3, p < 0.01; frontal cortex: t 10 = 5.6, p < 0.005), relative to their PBS controls. This was reflected in the overall ANOVA for frontal cortex by both the interaction between tumors and euflammation and tumors, euflammation, and LPS treatments approaching statistical significance ( F 1, 37 = 2.8, p = 0.1, F 1, 37 = 2.9, p = 0.1). In the overall ANOVA for the hypothalamus ( Fig. 4 h) , only LPS treatment independently increased Tnfα ( F 1, 37 = 75.1, p < 0.0001), although the interaction between euflammation and LPS treatments was also statistically significant ( F 1, 37 = 6.2, p < 0.05). Thus, LPS increased hypothalamic Tnfα in all mice relative to PBS-treated controls (U = 0, p < 0.01 for all cases), except for tumor-free mice treated with euflammation ( p > 0.05). Among PBS-treated mice, euflammation influenced hypothalamic Tnfα ( F 1, 18 = 8.2, p < 0.05), such that euflammation increased Tnfα within tumor-free mice only ( t 9 = 2.4, p < 0.05).
Cd11b. Cd11b is a marker of microglial number/activation and is therefore distinct from the other 3 proinflammatory cytokine genes. For Cd11b ( Fig. 4 j-l) , both euflammation and LPS treatment independently increased hippocampal Cd11b mRNA ( F 1, 36 = 21.7, p < 0.0001; F 1, 36 = 7.5, p < 0.01). Euflammation increased Cd11b within both LPS treatments and tumor treatments ( p < 0.05 in all cases), except this increase did not reach statistical significance for tumor-free LPS-treated mice between euflammation and no euflammation ( p = 0.08). LPS did not statistically significantly increase Cd11b mRNA among groups within the hippocampus ( p > 0.05 in all cases). In the hypothalamus, only euflammation treatment significantly altered Cd11b ( F 1, 38 = 10.0, p < 0.005), but both the interaction between tumors and LPS and among tumors, euflammation, and LPS treatments approached statistical significance ( F 1, 38 = 2.6, p = 0.1, F 1, 38 = 3.6, p = 0.06). Thus, euflammation increased Cd11b only in the hypothalamus of LPS-treated tumorbearing mice relative to no euflammation tumor-bearing controls (U = 4, p < 0.05), as well as compared to their tumor-free counterparts (U = 4, p < 0.05). Euflammation treatment also significantly altered frontal cortex Cd11b mRNA ( F 1, 37 = 4.3, p < 0.05), whereas tumor treatment approached statistical significance ( F 1, 37 = 3.5, p = 0.07). This effects of euflammation on frontal cortex Cd11b were driven by the PBS-treated controls. Within these controls, euflammation altered Cd11b gene expression in all 3 brain regions (hippocampal: F 1, 18 = 11.5, p < 0.01; hypothalamus: F 1, 19 = 5.8, p < 0.05; frontal cortex: F 1, 19 = 5.1, p < 0.05) such that euflammation increased hippocampal Cd11b for both tumor-free and -bearing mice and for tumor-free mice only in the hypothalamus ( p < 0.05 in all cases). No pairwise differences were found among PBStreated mice for the frontal cortex ( p > 0.05 in both cases).
Behavior
In the spontaneous alternation test, LPS treatment altered total distance traveled ( Fig. 5 a, F 1, 39 = 5.2, p < 0.05) such that total distance was reduced in all LPS-treated mice relative to their PBS-treated controls (no tumor/no euflammation: U = 8, p = 0.1; no tumor/euflammation: U = 5, p = 0.1; tumor/no euflammation: t 10 = 2.3, p < 0.05), except tumor-bearing mice with euflammation ( p > 0.05). Euflammation approached a significant overall effect on distance traveled ( F 1, 39 = 3.7, p = 0.06), driven by LPStreated mice, in which euflammation increased total distance traveled in the tumor-bearing mice relative to those without euflammation ( t 10 = 2.3, p < 0.05). While no over- all effects were statistically significant for the percentage of spontaneous alternations, based on a priori hypotheses, LPS reduced the percentage of spontaneous alternation only in tumor-bearing mice without the euflammation treatment (U = 6.5, p = 0.06). For all other groups, spontaneous alternation remained unperturbed by LPS treatment relative to their respective PBS-treated controls ( p > 0.05 in all cases). In the novel object recognition test, all treatment groups spent more time investigating the novel object, but no differences in the discrimination index (investigation of novel vs. familiar object) were observed among groups (online suppl. Fig. 1 ; for all online suppl. material, see www.karger.com/doi/10.1159/000479184; p > 0.05 in all cases). However, LPS and the interaction between LPS and euflammation were significant for the time spent investigating the novel ( F 1, 37 = 6.7, p < 0.05; F 1, 37 = 10.9, p < 0.005) and familiar objects ( F 1, 37 = 9.5, p < 0.005; F 1, 37 = 5.1, p < 0.05). This LPS-induced decrease in investigation was not specific to either object (i.e., independent of cognition) and is summarized by the time spent not investigating either object in which both LPS ( Fig. 5 b, F 1, 37 = 30.8, p < 0.0001) and the interaction between euflammation and LPS treatments ( F 1, 37 = 23.2, p < 0.0001) were significant. Thus, LPS increased time spent not investigating either object in the no euflammation groups only (no tumor: t 8 = 4.9, p < 0.005; tumor: t 9 = 6.8, p < 0.0001), whereas euflammation protected mice from this reduction in general investigation behavior.
LPS influenced hippocampal Bdnf mRNA ( Fig. 5 c; F 1, 36 = 6.1, p < 0.05), such that Bdnf was reduced by LPS in tumor-free controls without euflammation, whereas this reduction was prevented by the euflammation protocol ( p > 0.05). In contrast, the protective effects of euflammation on LPS-induced reductions in Bdnf tended to be absent in tumor-bearing mice ( t 10 = 2.1, p = 0.06).
Experiment 2: Effects of Euflammation on Tumors
Euflammation Protocol. Completion of the euflammation protocol prior to tumor induction did not alter final tumor mass (data not shown) or tumor growth (online suppl. Fig. 2a ; p > 0.05 for both). The subsequent immune challenge (LPS) occurred 23 days later in this experiment, and neither tumor nor euflammation treatments influenced neuroinflammation ( p > 0.05 in all cases). Only LPS significantly increased Il1β , Il6 , and Tnfα in all groups (e.g., hippocampal Il1β ; online suppl. Fig. 2b ; F 1, 23 = 40.9, p < 0.0001).
Discussion
This project was designed to be the first application of an established euflammatory protocol to a chronic disease model (i.e., cancer). In experiment 1, euflammation dramatically attenuated LPS-induced inflammatory responses in the control C3H strain of mice, similar to that reported previously in FVB mice only [2, 3] . Furthermore, euflammation was comparably effective, with respect to peripheral circulating inflammatory responses, even in the presence of a peripheral tumor. Like most solid peripheral tumors, these oral carcinomas are a continuous source of inflammatory signals and immune cells in situ [35, 36] . In spite of this additional burden on the immune system, conditioning of the peripheral innate immune system by the euflammation protocol successfully resulted in temporal dynamics of peripheral cytokine responses comparable to mice without tumors. Of note, the magnitude of peripheral cytokine responses tended to be higher among tumor-bearing mice for 3 out of 4 cytokines examined, however, not to a statistically significant degree. Additionally, these tumors were not metabolically taxing enough to alter body weight [26] , nor did euflammation treatment alter final tumor mass. Euflammation slightly attenuated weight gain, although euflammation-and LPS-induced splenomegaly [3, 37] remained similar between tumor-bearing and tumor-free mice.
In terms of brain inflammatory responses to LPS, tumors modestly altered the consequences of euflammation treatment. In general, euflammation reduced central inflammatory responses to LPS as predicted [2] , but these reductions failed to return to control-like levels for several markers in the tumor-bearing mice only (hypothalamic Il1β and Tnfα in all 3 brain regions examined). These data suggest that the modulating effects of tumors on euflammation-induced neuroinflammation may be cytokine specific (i.e., Il1β and Tnfα , but not Il6 ). Notably, neuroinflammatory changes driven by tumors did not stem from direct comparisons to tumor-free controls, but rather in that tumor-bearing mice treated with LPS differed from tumor-bearing PBS-treated controls, whereas the equivalent tumor-free groups remained comparable. This suggests that tumors either attenuate or delay euflammation-induced reductions in neuroinflammatory activation. Thus, euflammation was less effective in attenuating LPS-induced neuroinflammatory responses in tumor-bearing mice compared with tumor-free mice.
Using the nonspecific myeloid cell surface marker, Cd11b, to assess microglial status in the brain, both euflammation and LPS increased Cd11b mRNA in the hip-pocampus in the present study. Given that another microglia marker, Iba1, is reduced in brains of euflammation-treated mice in a previous study [2] , Cd11b may reflect the potential migration of peripheral myeloid cells, simply the upregulation of that particular adhesion marker on microglia, or a mouse strain difference. Other brain regions tested did not show this stepwise Cd11b gene expression response to treatments. While the likelihood that residual circulating immune cells significantly influenced the observed brain neuroinflammatory gene expression is low [38] , this possibility remains.
These oral tumors in the flank affected neither resting neuroinflammation nor LPS-induced inflammation in the absence of euflammation. Other peripheral tumors increase resting neuroinflammatory signals [39, 40] and a rat model of breast cancer is characterized by exaggerated neuroinflammatory responses to a peripheral LPS injection relative to tumor-free controls [22] . Larger tumor masses may be necessary for these increases in resting and triggered neuroinflammatory signals, as a positive association between tumor mass and neuroinflammation has been observed [22] .
Euflammation was protective against sickness behavior (locomotor activity) in both tumor-bearing and tumorfree mice as exemplified by their post-LPS disinterest in either object during the novel object test. Alternatively, euflammation appeared to be more protective in the tumor-bearing mice for locomotor activity (total distance traveled) after LPS in the Y-maze task relative to tumorfree mice and euflammation-free tumor-bearing mice. Of note, LPS only significantly reduced locomotion in the tumor-bearing mice in this test, indirectly suggesting that tumors may augment LPS-induced lethargy relative to tumor-free controls. Indeed, tumors increased anorexic sickness responses to LPS in rats [17] .
Acute cognitive impairments after LPS treatment have not been as extensively investigated as sickness behaviors and had not yet been studied in the context of euflammation. From the existing literature, studies report LPS-induced disruptions in spatial learning in a water maze [41] , novel object recognition, and spontaneous alternation 6 h to 7 days after a single high dose of LPS (600-800 μg/ kg) [30, 31, 42] , impairment of active avoidance after a common dose of LPS (250 μg/kg) [32, 43] , and impairment of contextual conditioning in rats [44] . These LPSinduced cognitive impairments appear to be driven by IL-1β [44, 45] . In the present study, the 250 μg/kg dose of LPS drove mild cognitive impairments in spontaneous alternation approximately 1.5-2 h after injection in the tumor-bearing mice only, which was rescued by euflammation. This cognitive effect is not confounded by potential differences in lethargy as overall locomotion is controlled for in its calculation (percent not absolute alternations). However, euflammation did not rescue associated LPS-induced decreases in hippocampal Bdnf in the tumor-bearing mice. Therefore, the protective effects of euflammation on tumor-induced cognitive responses to LPS were independent of hippocampal Bdnf and, potentially, neurogenesis mechanisms. BDNF is important for survival and growth of neurons, and its expression is correlated with learning. Effects of acute LPS on BDNF are mixed [46] [47] [48] . Indeed, other LPS and cognition studies have shown a discordance between hippocampal BDNF and learning [37] . Finally, cognitive changes in hippocampal-independent learning and memory based on tumors, euflammation, or LPS were absent in the novel object recognition task. This indicates that different types of cognitive function may vary in their susceptibility to being modulated by these factors. Taken together, these data suggest a preliminary interaction between tumors and LPS treatment on behavior. Thus, euflammation might recover behavioral differences observed in response to euflammation that are unmasked by a tumor. Indeed, behavioral deficits in cancer patients are often only unmasked after a physiological challenge. Given the low sample size (n = 6) in the present behavioral investigation, further replication of these findings is necessary.
Finally, the hypothesis that euflammation may reduce tumor initiation, growth, or later responses to an immune challenge was assessed in experiment 2. Indeed, the antitumor activity of repeated LPS or other bacterial toxins was initially reported in the 19th century [5, 49] . Therefore, the present rationale was that tumor initiation may be reduced by euflammation-induced reductions in local inflammatory responses, as local inflammation can drive tumorigenesis of oral and many other cancers [50, 51] . However, in experiment 2, no differences in tumor incidence (100%) or tumor growth rates were observed. Indeed, without a recent immune stimulus (e.g., LPS), local resting inflammation would likely not differ between mice treated with the euflammatory protocol and those without. Additionally, suppression of inflammation with the euflammatory protocol had only been investigated when the immune challenge (LPS) occurred immediately after euflammation. In experiment 2, the immune challenge was delayed almost 3 weeks after the euflammatory protocol and resulted in no attenuation of LPS-induced neuroinflammation. Therefore, the functional duration of reducing neuroinflammation using this 3-day euflammatory protocol is finite. Furthermore, while inflammatory responses to immune chal-lenges are attenuated after euflammation, peripheral macrophage function and number are enhanced [3] , resembling a more efficient macrophage response. While a potentially similar macrophage change may occur when euflammation is applied to a tumor model, it does not appear to alter tumor growth. However, peripheral macrophage efficiency may be relevant to other concurrent cancer-related immune functions (e.g., healing after surgery).
In summary, this research sought to apply a recently established euflammatory protocol, which modifies subsequent brain and behavioral responses in the absence of illness side effects, to the promising field of anticancer bacterial treatment, which is currently constrained by these negative side effects. Furthermore, while repeated exposure to bacterial toxins can successfully inhibit tumor biology, it had not been examined as a potential modifier of inflammation-induced behavioral changes reported in cancer populations. Here, we demonstrate that euflammation ameliorates neuroinflammatory signaling and select cognitive deficits unmasked by the presence of a tumor. Based on these results using an established E. coli -based euflammatory protocol, the potential development of a euflammatory protocol using other bacteria that are used clinically to reduce tumors (e.g., Salmonella , Clostridium ) is warranted. The potential prophylactic application of a subsymptomatic euflammatory protocol in susceptible populations may have the potential to prevent or attenuate debilitating behavioral comorbidities in addition to its antitumor applications.
